Glucocorticoid-induced osteoporosis

Silverman, Stuart L.; Lane, Nancy E.

doi:10.1007/s11914-009-0005-4

Cited by 50Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

Glucocorticoid-induced osteoporosis

Open access

Silverman, Stuart L., Lane, Nancy E.·2009·Current Osteoporosis Reports

DOI 10.1007/s11914-009-0005-4PMC PMC13592211

Open this paper in CoChat — free account

Abstract

Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s11914-009-0005-4

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucocorticoid use results in rapid trabecular bone loss and a high incident fracture risk.
“However, GC use results in rapid trabecular bone loss and a high incident fracture risk [1, 2].”
From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [2]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · see citing works
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · see citing works
Use of Inhaled Corticosteroids and Risk of Fractures
van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,297 · see citing works
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · see citing works
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263 · see citing works
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258 · see citing works
Self-citation
Estrogen deficiency and bone loss: an inflammatory tale
Weitzmann, M. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28550 · Cited by 990 · see citing works
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914 · see citing works
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 875 · see citing works
The Basophil Adenomas of the Pituitary Body and Their Clinical Manifestations (Pituitary Basophilism)
Cushing, H. (1964) · Journal of neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 849 · see citing works
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839 · see citing works
Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works
Outcomes of total hip and knee replacement: Preoperative functional status predicts outcomes at six months after surgery
Fortin, P. R., Clarke, A. E., Joseph, L., Liang, M. H., Tänzer, M., Ferland, D., Phillips, C., Partridge, A. J., B�lisle, P., Fossel, A. H., et al. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199908)42:8 · Cited by 708 · see citing works
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705 · see citing works
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. C. (2000) · Lara D. Veeken · doi:10.1093/rheumatology/39.12.1383 · Cited by 699 · see citing works
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W., Brown, J. P., Hanley, D. A., Hodsman, A. B., Josse, R. G., Kendler, D. L., Lentle, B. C., Olszynski, W. P., Ste‐Marie, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 683 · see citing works
Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK
Kanis, J. А., McCloskey, E. V., Johansson, H., Ström, O., Borgström, F., Odén, A., & National Osteoporosis Guideline Group (2008) · Osteoporosis International · doi:10.1007/s00198-008-0712-1 · Cited by 590 · see citing works
Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial
Reid, D. M., Hughes, R., Laan, R., Sacco-Gibson, N., Wenderoth, D., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 588 · see citing works
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584 · see citing works
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559 · see citing works
Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B. M., Kohler, J. A., & Fürst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540 · see citing works
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529 · see citing works
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527 · see citing works
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.
Lane, N. E., Sanchez, S., Modin, G. W., Genant, H. K., Pierini, E., & Arnaud, C. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3914 · Cited by 526 · see citing works
Self-citation
Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy
Wallach, S., Cohen, S. B., Reid, D. M., Hughes, R., Hosking, D. J., Laan, R., Doherty, S. M., Maricic, M. J., Rosen, C. J., Brown, J. P., et al. (2000) · Calcified Tissue International · doi:10.1007/s002230001146 · Cited by 512 · see citing works
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493 · see citing works
Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis
Laan, R., van Riel, P. L. C. M., van de Putte, L. B. A., van Erning, L. J. T. O., Hof, M. A. V., & Lemmens, J. A. M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00001 · Cited by 410 · see citing works
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
Compston, J. E., Cooper, A., Cooper, C. C., Francis, R. M., Kanis, J. A., Marsh, D., McCloskey, E. V., Reid, D. M., Selby, P. L., & Wilkins, M. (2009) · Maturitas · doi:10.1016/j.maturitas.2008.11.022 · Cited by 405 · see citing works
Testosterone Therapy in Glucocorticoid-Treated Men
Reid, I. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440100065008 · Cited by 369 · see citing works
Inhaled corticosteroid use and bone-mineral density in patients with asthma
Wong, C., Walsh, L. J., Smith, C. J., Wisniewski, A. F. Z., Lewis, S., Hubbard, R., Cawte, S. A., Green, D. J., Pringle, M., & Tattersfield, A. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02138-3 · Cited by 361 · see citing works
INTERMITTENT ETIDRONATE THERAPY TO PREVENT CORTICOSTEROID- INDUCED OSTEOPOROSIS
Dachi, J. O. D. A., Ensen, W. I. G. B., Acques, J., Rown, B., Anley, D. A. H., Osse, R. O. J., Endler, D. A. L. K., Entle, B. R. L., Lszynski, W. O. O., Ouis, L., et al. (1997) · Cited by 360 · see citing works
Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice
Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355 · see citing works
Self-citation
Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Carbonare, L. D., Arlot, M. E., Chavassieux, P. M., Roux, J. P., Portero, N. R., & Meunier, P. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.97 · Cited by 309 · see citing works
Calcium and Vitamin D 3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis
Buckley, L. M., Leib, E. S., Cartularo, K. S., Vacek, P. M., & Cooper, S. M. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-12-199612150-00004 · Cited by 309 · see citing works
Effects of inhaled glucocorticoids on bone density in premenopausal women.
Israel, E., Banerjee, T. R., Fitzmaurice, G. M., Kotlov, T. V., LaHive, K., & LeBoff, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002304 · Cited by 303 · see citing works
Fracture risk with intermittent high‐dose oral glucocorticoid therapy
de Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C. C., & van Staa, T. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22294 · Cited by 297 · see citing works
Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study
van Staa, T. P., van Staa, T. P., van Staa, T. P., Leufkens, H. G. M., & Cooper, C. C. (2002) · Osteoporosis International · doi:10.1007/s001980200084 · Cited by 292 · see citing works
Oral glucocorticoid use is associated with an increased risk of fracture
Steinbuch, M., Youket, T. E., & Cohen, S. B. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1548-3 · Cited by 280 · see citing works
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts
Ohnaka, K., Tanabe, M., Kawate, H., Nawata, H., & Takayanagi, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.117 · Cited by 270 · see citing works
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice
Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M. C., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23454 · Cited by 241 · see citing works
Self-citation
Bone Mass Continues to Increase at the Hip After Parathyroid Hormone Treatment Is Discontinued in Glucocorticoid-Induced Osteoporosis: Results of a Randomized Controlled Clinical Trial
Lane, N. E., Sanchez, S., Modin, G. W., Genant, H. K., Pierini, E., & Arnaud, C. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.944 · Cited by 231 · see citing works
Self-citation
Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
Hall, G. M., Daniels, M., Doyle, D., & Spector, T. D. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371014 · Cited by 228 · see citing works
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.
Adachi, J. D., Wg, B., Bianchi, F. A., Cividino, A. A., Pillersdorf, S., Sebaldt, R. J., Tugwell, P., Gordon, M., Steele, M., Webber, C., et al. (1996) · PubMed · Cited by 209 · see citing works
THE SCIENCE AND THERAPY OF GLUCOCORTICOID-INDUCED BONE LOSS
Lane, N. E., & Lukert, B. P. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70017-7 · Cited by 209 · see citing works
Self-citation
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates
Dore, R. K., Cohen, S. B., Lane, N. E., Palmer, W. E., Shergy, W. J., Zhou, L., Wang, H., Tsuji, W. H., & Newmark, R. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.112920 · Cited by 194 · see citing works
Self-citation
Inhaled Corticosteroids and Hip Fracture: A Population-based Case–Control Study
Hubbard, R., Smith, C. J. P., Smeeth, L. L., Harrison, T. W., & Tattersfield, A. E. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-606oc · Cited by 193 · see citing works
Decreased Bone Mineral Density in Premenopausal Asthma Patients Receiving Long-term Inhaled Steroids
Ip, M., Lam, K. S. L., Yam, L., Kung, A. W., & Ng, M. (1994) · CHEST Journal · doi:10.1378/chest.105.6.1722 · Cited by 177 · see citing works
Modulation of Dickkopf-1 Attenuates Glucocorticoid Induction of Osteoblast Apoptosis, Adipocytic Differentiation, and Bone Mass Loss
Wang, F., Ko, J., Yeh, D., Ke, H.-C., & Wu, H.-L. (2008) · Endocrinology · doi:10.1210/en.2007-0910 · Cited by 173 · see citing works
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study
Ringe, J. D., Dorst, A., Faber, H., Ibach, K., & Sorenson, F. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1425-0 · Cited by 168 · see citing works
Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression
Pereira, R. C., Delany, A. M., & CANALIS, E. M. (2002) · Bone · doi:10.1016/s8756-3282(02)00687-7 · Cited by 163 · see citing works
Inhaled corticosteroids: benefits and risks.
Geddes, D. M. (1992) · Thorax · doi:10.1136/thx.47.6.404 · Cited by 160 · see citing works
Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1-Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone
Boutsen, Y., Jamart, J., Esselinckx, W., & Devogelaer, J.-P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.104 · Cited by 160 · see citing works
The Basophil Adenomas of the Pituitary Body and Their Clinical Manifestations (Pituitary Basophilism)1
Cushing, H. (1994) · Obesity Research · doi:10.1002/j.1550-8528.1994.tb00097.x · Cited by 154 · see citing works
Glucocorticoid Suppression of IGF I Transcription in Osteoblasts
Delany, A. M., Durant, D., & CANALIS, E. M. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.10.0704 · Cited by 153 · see citing works
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patients
Curtis, J. R., Westfall, A. O., Allison, J. J., Becker, A., Casebeer, L. L., Freeman, A. N., Spettell, C. M., Weissman, N., Wilke, S., & Saag, K. G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21194 · Cited by 151 · see citing works
VERTEBRAL FRACTURES RESULTING FROM PROLONGED CORTISONE AND CORTICOTROPIN THERAPY
Curtiss, P. H. (1954) · JAMA · doi:10.1001/jama.1954.02950050007002 · Cited by 150 · see citing works
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
Devogelaer, J., Goemaere, S., Boonen, S., Body, J., Kaufman, J., Reginster, J., Rozenberg, S., & Boutsen, Y. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2032-z · Cited by 144 · see citing works
Management of glucocorticoid‐induced osteoporosis in patients with rheumatoid arthritis: Rates and predictors of care in an academic rheumatology practice
Solomon, D. H., Katz, J. N., Jacobs, J. P., Tourette, A. M. L., & Coblyn, J. S. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10613 · Cited by 137 · see citing works
Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind
Manolagas, S. C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1001 · Cited by 135 · see citing works
Race and Ethnic Variation in Proximal Femur Structure and BMD Among Older Men
Marshall, L. M., Zmuda, J. M., Chan, B. K. S., Barrett-Connor, E. L., Cauley, J. A., Ensrud, K. E., Lang, T., & ORWOLL, E. S. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070908 · Cited by 131 · see citing works
A Randomized Controlled Trial of Salmon Calcitonin to Prevent Bone Loss in Corticosteroid-Treated Temporal Arteritis and Polymyalgia Rheumatica
Healey, J. H., Paget, S. A., Williams-Russo, P. G., Szatrowski, T. P., Schneider, R. J., Spiera, H., Mitnick, H. J., Aleš, K. L., & Schwartzberg, P. (1996) · Calcified Tissue International · doi:10.1007/bf02529727 · Cited by 128 · see citing works
Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients
Montemurro, L., Schiraldi, G., Fraioli, P., Tosi, G., Riboldi, A., & Rizzato, G. (1991) · Calcified Tissue International · doi:10.1007/bf02565124 · Cited by 125 · see citing works
The Comparative Efficacy of Drug Therapies Used for the Management of Corticosteroid-Induced Osteoporosis: A Meta-Regression
Amin, S., LaValley, M. P., Simms, R. W., & Felson, D. T. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.8.1512 · Cited by 124 · see citing works
Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies
de Nijs, R. N. J., Jacobs, J. W. G., Algra, A., Lems, W. F., & Bijlsma, J. W. J. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1614-5 · Cited by 124 · see citing works
Cortisol Increases Interstitial Collagenase Expression in Osteoblasts by Post-transcriptional Mechanisms
Delany, A. M., Jeffrey, J. J., Rydziel, S., & CANALIS, E. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.44.26607 · Cited by 121 · see citing works
Gene expression profiling of glucocorticoid-inhibited osteoblasts
Leclerc, N., Luppen, C., Ho, V., Nagpal, S., Hacia, J., Smith, E., & Frenkel, B. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0330175 · Cited by 116 · see citing works
Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
Luengo, M., Pons, F., de Osaba, M. J. M., & Picado, C. (1994) · Thorax · doi:10.1136/thx.49.11.1099 · Cited by 111 · see citing works
Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs
Adler, R. A., & Hochberg, M. C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2619 · Cited by 105 · see citing works
A chimeric antibody with the human ?1 constant region as a putative standard for assays to detect IgG ?2-glycoprotein I-dependent anticardiolipin and anti-?2-glycoprotein I antibodies
Ichikawa, K., Tsutsumi, A., Atsumi, T., Matsuura, E., Kobayashi, S., Hughes, G. R. V., Khamashta, M. A., & Koike, T. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199911)42:11 · Cited by 88 · see citing works
Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate
Herrala, J., Puolijoki, H., Impivaara, O., Liippo, K. K., Tala, E., & Nieminen, M. M. (1994) · Bone · doi:10.1016/8756-3282(94)90309-3 · Cited by 82 · see citing works
Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial
Mok, C. C., Ying, K. Y., To, C. H., Ho, L. Y., Yu, K. L., Lee, H. K., & M., K. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143453 · Cited by 78 · see citing works
Histomorphometric analysis of glucocorticoid-induced osteoporosis
Carbonare, L. D., Bertoldo, F., Valenti, M. T., Zenari, S., Zanatta, M., Sella, S., Giannini, S., & Cascio, V. L. (2005) · Micron · doi:10.1016/j.micron.2005.07.009 · Cited by 71 · see citing works
Cortisol Inactivation by 11β-Hydroxysteroid dehydrogenase-2 May Enhance Endometrial Angiogenesis via Reduced Thrombospondin-1 in Heavy Menstruation
Rae, M. T., Mohamad, A., Price, D., Hadoke, P. W. F., Walker, B. R., Mason, J. I., Hillier, S. G., & Critchley, H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1879 · Cited by 57 · see citing works
Glucocorticoid-Induced Osteoporosis: From Basic Mechanisms to Clinical Aspects
Alesci, S., Martino, M. U. D., Ilias, Ι., Gold, P. W., & Chrousos, G. P. (2005) · NeuroImmunoModulation · doi:10.1159/000082360 · Cited by 48 · see citing works
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science
Compston, J. E., Reid, D. M., Boisdron, J., Brandi, M. L., Burlet, N., Cahall, D. L., Delmas, P. D., Dere, W. H., Devogelaer, J.-P., Fitzpatrick, L. A., et al. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0670-7 · Cited by 30 · see citing works
The use of inhaled corticosteroids is not associated with an increased risk of fracture in children.
van Staa, T. P., Cooper, C. M., Leufkens, H. G. M., & Bishop, N. J. (2001) · Journal of Bone and Mineral Research · Cited by 17 · see citing works
The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids.
van Staa, T. P., Eastell, R., Barton, I. P., Rizzoli, R., Javaid, M. K., & Cooper, C. C. (2003) · Journal of Bone and Mineral Research · Cited by 5 · see citing works
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study
Warrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2 · see citing works
Self-citation
Untitled work
Santiago (2001) · doi:10.1002/1529-0131(200107)44:7

Flagged first, then by citations

2 of the 81 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Reid DM, Devogelaer J, Saag K,: Effect of a single infusion of zoledronic acid 5mg versus oral risedronate 5mg on bone mineral density at lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid induced osteoporosis [abstract F403]. J Bone Miner Res 2008, 23: s122. This is a randomized, controlled clinical trial of individuals on glucocorticoids and with osteopenia who were treated with intravenous zoledronic acid or oral risedronate. Zoledronic acid–treated patients had a greater increase in lumbar spine and hip BMD compared with the risedronate-treated patients. Therefore, in patients on glucocorticoids who could take an oral medication, zoledronic acid (administered intravenously) was rapid in onset and improved bone mass.
Saag KM, Zanchetta JR, Devogelaer J,: Teriparatide versus alendronate for treatment of glucocorticoid induced osteoporosis: 36 month results [abstract 1171]. J Bone Miner Res 2008, 23: s49. This abstract was presented in September 2008 at the American Society of Bone and Mineral Resarch. It reported on individuals on glucocorticoids who were randomly assigned to teriparatide or alendronate for 36 months. Those on teriparatide continued to have a reduced risk of incident vertebral fractures compared with individuals treated with alendronate for 36 months.

Sorted by citations

Growth, immune, antioxidant, and bone responses of heat stress-exposed broilers fed diets supplemented with tomato pomace
Hosseini-Vashan, S. J., Golian, A., & Yaghobfar, A. (2015) · International Journal of Biometeorology · doi:10.1007/s00484-015-1112-9 · Cited by 159 · see citing works
ACTH protects against glucocorticoid-induced osteonecrosis of bone
Zaidi, M., Sun, L., Robinson, L. J., Tourkova, I. L., Liu, L., Wang, Y., Zhu, L.-L., Liu, X., Li, J., Peng, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912176107 · Cited by 148 · see citing works
Pathogenic mechanisms of glucocorticoid-induced osteoporosis
Chen, M., Fu, W., Xu, H., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.002 · Cited by 146 · see citing works
Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review
Martinis, M. D., Allegra, A., Sirufo, M., Tonacci, A., Pioggia, G., Raggiunti, M., Ginaldi, L., & Gangemi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168855 · Cited by 120 · see citing works
Chronic intervillositis of the placenta: A systematic review
Contro, E., deSouza, R., & Bhide, A. (2010) · Placenta · doi:10.1016/j.placenta.2010.10.005 · Cited by 100 · see citing works
Postmenopausal osteoporosis in rheumatoid arthritis: The estrogen deficiency-immune mechanisms link
Sapir‐Koren, R., & Livshits, G. (2017) · Bone · doi:10.1016/j.bone.2017.06.020 · Cited by 97 · see citing works
Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle
Søe, K., & Delaissé, J. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.113 · Cited by 96 · see citing works
ACTH is a novel regulator of bone mass
Isales, C. M., Zaidi, M., & Blair, H. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05231.x · Cited by 83 · see citing works
Protection against Glucocorticoid-Induced Damage in Human Tenocytes by Modulation of ERK, Akt, and Forkhead Signaling
Poulsen, R. C., Carr, A. J., & Hulley, P. A. (2011) · Endocrinology · doi:10.1210/en.2010-1087 · Cited by 77 · see citing works
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 63 · see citing works
IL-4 administration exerts preventive effects via suppression of underlying inflammation and TNF-α-induced apoptosis in steroid-induced osteonecrosis
Wu, X., Feng, X., He, Y., Gao, Y., Yang, S., Shao, Z., Yang, C., Wang, H., & Ye, Z. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3474-6 · Cited by 46 · see citing works
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 36 · see citing works
Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study
Karras, D., Stoykov, I., Lems, W. F., Langdahl, B. L., Ljunggren, Ö., Barrett, A., Walsh, J. B., Fahrleitner‐Pammer, A., Rajzbaum, G., Jakob, F. J., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110947 · Cited by 35 · see citing works
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis
Roux, C., Reid, D. M., Devogelaer, J. P., Saag, K. G., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Bucci-Rechtweg, C. M., Su, G., & Sambrook, P. N. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1800-1 · Cited by 33 · see citing works
Synergistic antiosteoporotic effect of Lepidium Sativum and alendronate in glucocorticoid-induced osteoporosis in wistar rats
Elshal, M. F., Almalki, A., Hussein, H., & Khan, J. A. (2013) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v10i5.8 · Cited by 32 · see citing works
Low Bone Mineral Density, But Not Epidural Steroid Injection, Is Associated with Fracture in Postmenopausal Women with Low Back Pain
Hwang, B. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/441 · Cited by 32 · see citing works
Prevention of glucocorticoid induced bone changes with beta-ecdysone
Dai, W., Jiang, L., Lay, Y.-A. E., Chen, H., Jin, G., Zhang, H., Kot, A., Ritchie, R. O., Lane, N. E., & Yao, W. (2015) · Bone · doi:10.1016/j.bone.2015.01.001 · Cited by 30 · see citing works
Self-citation
Age-Related Loss in Bone Mineral Density of Rats Fed Lifelong on a Fish Oil-Based Diet Is Avoided by Coenzyme Q10 Addition
Varela‐López, A., Ochoa, J. J., Elvira, J. M. L., López‐Frías, M., Planells, E., Ramírez-Tortosa, M. C., Ramírez-Tortosa, C. L., Giampieri, F., Battino, M. A., & Quiles, J. L. (2017) · Nutrients · doi:10.3390/nu9020176 · Cited by 25 · see citing works
Rheumatic manifestations of endocrine disease
Chakravarty, S. D., & Markenson, J. A. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835b4f3f · Cited by 25 · see citing works
Comparative performance analysis of large language models: ChatGPT-3.5, ChatGPT-4 and Google Gemini in glucocorticoid-induced osteoporosis
Tong, L., Zhang, C., Liu, R., Yang, J. N., & Sun, Z. (2024) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-04996-2 · Cited by 24 · see citing works
Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series
Schuemie, M. J., Trifirò, G., Coloma, P. M., Ryan, P. B., & Madigan, D. (2014) · Statistical Methods in Medical Research · doi:10.1177/0962280214527531 · Cited by 24 · see citing works
Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density
Grahnemo, L., Jochéms, C., Andersson, A., Engdahl, C., Ohlsson, C., Islander, U., & Carlsten, H. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0508 · Cited by 24 · see citing works
Rheumatic manifestations of endocrine diseases
Markenson, J. A. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328333dd38 · Cited by 23 · see citing works
Strain-specific differences in the development of bone loss and incidence of osteonecrosis following glucocorticoid treatment in two different mouse strains
Shidara, K., Mohan, G., Lay, Y.-A. E., Jepsen, K. J., Yao, W., & Lane, N. E. (2018) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2018.07.001 · Cited by 22 · see citing works
Self-citation
Cortical bone density and thickness alterations by high-resolution peripheral quantitative computed tomography: association with vertebral fractures in primary Sjögren’s syndrome
Pasoto, S. G., Augusto, K. L., Alvarenga, J. C., Takayama, L., de Oliveira, R. M., Bonfá, E., & Pereira, R. M. R. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew332 · Cited by 22 · see citing works
Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study
Schwetz, V., Schnedl, C., Urbanic-Purkart, T., Trummer, C., Dimai, H. P., Fahrleitner‐Pammer, A., Putz‐Bankuti, C., Christopher, K. B., Obermayer-Pietsch, B. M., Pieber, T. R., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4190-1 · Cited by 18 · see citing works
β‑ecdysterone promotes autophagy and inhibits apoptosis in osteoporotic rats
Tang, Y., Yue, Z., Xin, D., Zeng, L., Xiong, Z., Hu, Z., & Xu, C. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8053 · Cited by 17 · see citing works
Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome
Salman-Monte, T. C., Sánchez‐Piedra, C., Castro, M. F., Andreu, J. L., Taboada, V. M. M., Olivé, A., Rosas, J., Menor, R., Rodríguez, B., Garcia-Aparicio, Á., et al. (2020) · Rheumatology International · doi:10.1007/s00296-020-04615-3 · Cited by 17 · see citing works
G-CSF/SCF exert beneficial effects via anti-apoptosis in rabbits with steroid-associated osteonecrosis
Wu, X., Yang, S., Wang, H., Meng, C., Xu, W., Duan, D., & Liu, X. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.06.003 · Cited by 15 · see citing works
Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors
Byreddy, D. V., Bouchonville, M. F., & Lewiecki, E. M. (2015) · Climacteric · doi:10.3109/13697137.2015.1103615 · Cited by 14 · see citing works
Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis
Karahan, S. Z., Boz, C., Kilic, S., Usta, N. C., Özmenoğlu, M., Cakmak, V. A., & Gazioğlu, S. (2016) · Multiple Sclerosis International · doi:10.1155/2016/5794910 · Cited by 14 · see citing works
No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model
Carvas, J. B., Pereira, R. M. R., Bonfá, E., Silveira, C. A., Lima, L. L., Caparbo, V. F., & de Mello, S. B. V. (2011) · Clinics · doi:10.1590/s1807-59322011000600023 · Cited by 13 · see citing works
CYP24A1 Regulation in Health and Disease
Petkovich, M. P., Helvig, C. F., & Epps, T. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-381978-9.10080-0 · Cited by 12 · see citing works
Adherence and Efficacy of Screening for Low Bone Mineral Density Among Ulcerative Colitis Patients Treated With Corticosteroids
Khan, N. H., Abbas, A. M., Almukhtar, R., Cole, E. B., & Khan, A. N. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.486 · Cited by 12 · see citing works
Effects of glucocorticoid treatment on bone strength
Manolides, A. S., Cullen, D. M., & Akhter, M. P. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0156-5 · Cited by 12 · see citing works
Elevated HDL cholesterol levels are associated with osteoporosis in lung transplant candidates with chronic obstructive pulmonary disease
Reed, R. M., Wise, R. A., Dobs, A. S., Lechtzin, N., & Girgis, R. E. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.08.004 · Cited by 8 · see citing works
Effect of long-term low dose prednisolone administration on bone mineral density: Relating to non-compliant women with rheumatoid arthritis.
Heidari, B., Heidari, P., Hajian‐Tilaki, K., Bayani, M. A., & Babaei, M. (2018) · Europe PMC (PubMed Central) · doi:10.22088/cjim.9.2.171 · Cited by 5 · see citing works
Effect of Co-administration of Aconiti Lateralis Preparata Radix and Cinnamomi Cortex on Osteoclast Differentiation
Jung, G.-E., Kim, J. Y., Kim, J., Han, S., & Kim, Y.-K. (2014) · The Korea Journal of Herbology · doi:10.6116/kjh.2014.29.2.61 · Cited by 4 · see citing works
Percutaneous vertebroplasty in a series of myasthenic patients with steroid-induced symptomatic vertebral fractures
Maggi, L., Faragò, G., Mantegazza, R., & Ciceri, E. F. M. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1417-6 · Cited by 4 · see citing works
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate
Sambrook, P. N., Roux, C., Devogelaer, J.-P., Saag, K., Lau, C.-S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012) · Bone · doi:10.1016/j.bone.2011.10.024 · Cited by 3 · see citing works
Pharmacologic treatment of osteoporosis – 2011
Lakatos, P. L. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29111 · Cited by 3 · see citing works
Arthritis Accompanying Endocrine and Metabolic Disorders
Chakravarty, S. D., & Markenson, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00122-4 · Cited by 3 · see citing works
Osteoporosis-Related Simultaneous Four Joints Fractures and Dislocation after a Seizure: A Case Report
AlOmran, A. S. (2010) · Journal of Osteoporosis · doi:10.4061/2010/808341 · Cited by 2 · see citing works
Glicocorticoides e osteoporose – artigo de revisão
de Souza, M. C., Assemany, F. S., Lima, A. T. C., & de Souza, R. F. (2010) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v9i1.4734
Prevenzioneetrattamentodell'osteoporosi indottadaglucocorticoidinellarealtà ItalianaeinquellaInternazionale Prevention and treatment of glucocorticoid-induced osteoporosis in International and Italian scenarios
Munno, O. D., & Sedie, A. D. (2011)
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
de Reumatología, S., de Haya, C. T., & la Investigación, U. D. R. D. I. C. P. (2011)
Glucocorticoid‐induced Osteoporosis
Silverman, S. L., & Venuturupalli, S. (2013) · Wiley eBooks · doi:10.1002/9781118316290.ch6
Self-citation
Current World Literature
(2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328334b3e8
Anti-osteoporotic impact of Lepidium sativum seed extract and green-synthesized silver nanoparticles in a rat model of osteoporosis: possible TNF-α/RANKL modulation
Rekaby, M. H. A., El-Tantawi, H. G., Badr, G. M., Darwish, S. K., & El-Kareem, H. F. A. (2026) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2026.2711174

Treatment of glucocorticoid-induced osteoporosis
Mazziotti, G., Giustina, A., CANALIS, E. M., & Bilezikian, J. P. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09343222 · Cited by 13 · see citing works
New possibilities for the treatment of glucocorticoid-induced osteoporosis
Baranova, I. A. (2014) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2014-2-107-110 · Cited by 1 · see citing works
Glucocorticoid-induced osteoporosis and Cushing’s syndrome
Saag, K. G., Adler, R. A., & Weinstein, R. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00045-9
Glucocorticoid-Induced osteoporosis: clinical and therapeutic aspects
Mazziotti, G., Giustina, A., CANALIS, E. M., & Bilezikian, J. P. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000800028 · Cited by 45 · see citing works
ԳԼՅՈՒԿՈԿՈՐՏԻԿՈԻԴ-ԻՆԴՈՒԿՑՎԱԾ ՕՍՏԵՈՊՈՐՈԶԻ ԱՐԴԻԱԿԱՆՈՒԹՅՈՒՆԸ, ԿԱՆԽԱՐԳԵԼՄԱՆ ԵՎ ԲՈՒԺՄԱՆ ԺԱՄԱՆԱԿԱԿԻՑ ՄՈՏԵՑՈՒՄՆԵՐԸ
Էֆրեմիդու, Մ. Լ., Օսիպյան, Մ. Ա., Ղազինյան, Ի. Ս., & Գինոսյան, Ք. Վ. (2022) · MEDICINE SCIENCE AND EDUCATION · doi:10.56936/18291775-2022.34-37

Authors: Silverman, S. L., & Lane, N. E.
Affiliations: Cedars-Sinai Medical Center (US)
Corresponding author: Silverman, Stuart L.
ORCID: Silverman, Stuart L.
Lane, Nancy E.
Venue: Current Osteoporosis Reports
Publisher: Springer Science and Business Media LLC
Published: 2009-03
Volume: 7
Issue: 1
Pages: 23-26
ISSN: 1544-1873 (ISSN-L)
1544-2241
DOI: 10.1007/s11914-009-0005-4
PMC: PMC13592211
OpenAlex: W2083168044
Cited by: 50
References: 81
Citations by year: 2026: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 5
FWCI: 1.50
Type: journal article
Language: en
Open access: green
pmc.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Current Osteoporosis Reports (publishedVersion)
PubMed (publishedVersion)
PubMed Central (publishedVersion)
Funders: National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR043052, P50AR063043, K24AR048841, 2K24 AR 48841)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD051958)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: glucocorticoid-induced osteoporosis, osteoporotic fractures, bone metabolism, risk factors, bisphosphonates, teriparatide, pathophysiology
MeSH terms: Administration, Oral, Bone and Bones, Calcium, Diphosphonates, Glucocorticoids, Humans, Osteoporosis, Vitamin D, Teriparatide, Alendronate, Dietary Supplements, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glucocorticoid-induced osteoporosis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks